Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 191

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 191
---
 1,257 516 1,773 Neuromodulation847 259 1,106 736 240 976 715 202 917 MedSurg4,054 1,939 5,993 3,617 1,805 5,422 3,312 1,599 4,911 Interventional Cardiology Therapies824 1,820 2,645 743 1,674 2,417 744 1,485 2,228 Watchman1,371 145 1,516 1,155 119 1,274 915 103 1,019 Cardiac Rhythm Management1,403 876 2,279 1,405 813 2,218 1,337 763 2,100 Electrophysiology1,256 648 1,904 370 430 800 275 310 585 Cardiology4,855 3,490 8,344 3,673 3,036 6,709 3,271 2,662 5,932 Peripheral Interventions1,301 1,109 2,410 1,135 975 2,110 1,048 850 1,899 Cardiovascular6,156 4,599 10,755 4,808 4,011 8,819 4,319 3,512 7,831 Other(1)— — — — — — — — (60)Total Net Sales$10,210 $6,538 $16,747 $8,425 $5,816 $14,240 $7,632 $5,111 $12,682 (1)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes.Refer to Note M – Segment Reporting for information on our reportable segments.Year Ended December 31,Geographic Regions202420232022U.S.$10,210 $8,425 $7,632 Europe, Middle East and Africa3,228 2,856 2,526 Asia-Pacific2,686 2